Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;54(8):538-549.
doi: 10.1111/cea.14489. Epub 2024 Jun 27.

Role of IL-5 in asthma and airway remodelling

Rola AbuJabal  1 , Rakhee K Ramakrishnan  1 , Khuloud Bajbouj  1   2   3 , Qutayba Hamid  1   2   4
Affiliations
Review

Role of IL-5 in asthma and airway remodelling

Rola AbuJabal et al. Clin Exp Allergy. 2024 Aug.

Abstract

Asthma is a common and burdensome chronic inflammatory airway disease that affects both children and adults. One of the main concerns with asthma is the manifestation of irreversible tissue remodelling of the airways due to the chronic inflammatory environment that eventually disrupts the whole structure of the airways. Most people with troublesome asthma are treated with inhaled corticosteroids. However, the development of steroid resistance is a commonly encountered issue, necessitating other treatment options for these patients. Biological therapies are a promising therapeutic approach for people with steroid-resistant asthma. Interleukin 5 is recently gaining a lot of attention as a biological target relevant to the tissue remodelling process. Since IL-5-neutralizing monoclonal antibodies (mepolizumab, reslizumab and benralizumab) are currently available for clinical use, this review aims to revisit the role of IL-5 in asthma pathogenesis at large and airway remodelling in particular, in addition to exploring its role as a target for biological treatments.

Keywords: Interleukin‐5 (IL‐5); airway remodelling; anti‐IL5; asthma; fibrosis.

PubMed Disclaimer

References

REFERENCES

    1. Wu TD, Brigham EP, McCormack MC. Asthma in the primary care setting. Med Clin North Am. 2019;103(3):435‐452.
    1. 2022 GINA Report. Global Strategy for Asthma Management and Prevention. 2022 https://ginasthma.org/wp‐content/uploads/2022/07/GINA‐Main‐Report‐2022‐F...
    1. Normansell R, Kew KM, Stovold E. Interventions to improve adherence to inhaled steroids for asthma. Cochrane Database Syst Rev. 2017;2017(4):CD012226.
    1. Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5:S2‐S6.
    1. Fahy JV. Type 2 inflammation in asthma‐present in most, absent in many. Nat Rev Immunol. 2015;15(1):57‐65.